Science - USA (2020-08-21)

18. C. P. Bradleyet al.,Cell Host Microbe 22 , 697–704.e4 (2017).


19. S. Viaudet al.,Science 342 , 971–976 (2013).


20. M. G. Weinbauer,FEMS Microbiol. Rev. 28 , 127–181 (2004).


21. M. Piuri, G. F. Hatfull,Mol. Microbiol. 62 , 1569– 1585
    (2006).


22. M. Belcaid, A. Bergeron, G. Poisson,BMC Bioinformatics 12
    (Suppl 9), S10 (2011).


23. G. Y. Leeet al.,Cancer Res. 74 , 3114–3126 (2014).


24. Y.-C. Cheng, W.-C. Tsai, Y.-C. Sung, H.-H. Chang, Y. Chen,
    Cell. Physiol. Biochem. 45 , 819–831 (2018).


25. X. Zhanget al.,Tumour Biol. 39 , 1010428317705767
    (2017).


26. H. Wanget al.,Oncol. Rep. 40 , 2343–2352 (2018).


27. E. Pasolliet al.,Nat. Methods 14 , 1023–1024 (2017).


28. E. Pasolliet al.,Cell 176 , 649–662.e20 (2019).


29. B. Samb-Baet al.,PLOS ONE 9 , e87419 (2014).


30. T. J. Kelly, A. L. Souza, C. B. Clish, P. Puigserver,Mol. Cell. Biol.
    31 , 2696–2706 (2011).


31. Z. Fenget al.,Histopathology 64 , 348–355 (2014).


32. S.-C. Liuet al.,Cell Death Dis. 5 , e1485 (2014).


33. T. M. Greilinget al.,Sci. Transl. Med. 10 , eaan2306 (2018).


34. M. F. Koniget al.,Sci. Transl. Med. 8 , 369ra176 (2016).


35. J. Liet al.,Nat. Biotechnol. 32 , 834–841 (2014).


36. M. L. Pedullaet al.,Cell 113 , 171–182 (2003).


37. K. E. Wommack, R. R. Colwell,Microbiol. Mol. Biol. Rev. 64 ,
    69 – 114 (2000).

ACKNOWLEDGMENTS
We are thankful to the animal facility team of Gustave Roussy and
all the technicians from Centre GF Leclerc. We are indebted to
O. Kepp for figure design and to H. G. Rammensee (University
of Tübingen, Germany) for his careful guidance in peptide selection
and reading of the paper.Funding:L.Z. and G.K. were supported

by RHU Torino Lumière (ANR-16-RHUS-0008), ONCOBIOME

H2020 network, the Seerave Foundation, the Ligue contre le

Cancer (équipe labelisée); Agence Nationale de la Recherche

(ANR)–Projets blancs; ANR Francogermanique ANR-19-CE15-

0029 under the frame of E-Rare-2, the ERA-Net for Research on

Rare Diseases; Association pour la recherche sur le cancer (ARC);

Cancéropôle Ile-de-France; Fondation pour la Recherche Médicale

(FRM); a donation by Elior; the European Research Council (ERC);

Fondation Carrefour; High-end Foreign Expert Program in China

(GDW20171100085 and GDW20181100051), Institut National du

Cancer (INCa); Inserm (HTE); Institut Universitaire de France;

LeDucq Foundation; the LabEx Immuno-Oncology; the SIRIC

Stratified Oncology Cell DNA Repair and Tumor Immune

Elimination (SOCRATE); CARE network (directed by X. Mariette,

Kremlin Bicêtre AP-HP), and the SIRIC Cancer Research and

Personalized Medicine (CARPEM). The results shown here are

based upon data generated by the TCGA Research Network:

http://cancergenome.nih.gov/. I.C. was supported by National

Research, Development and Innovation Fund of Hungary Project

(no. FIEK_16-1-2016-0005). Z.S. was supported by the Research

and Technology Innovation Fund (NAP2-2017-1.2.1-NKP-0002) and

Breast Cancer Research Foundation (BCRF-17-156). Z.S. and I.C.

were supported by the Novo Nordisk Foundation Interdisciplinary

Synergy Programme Grant (NNF15OC0016584). P.N. was

supported by the Italian Association for Cancer Research (AIRC IG

19822). Mouse TCR sequencing was performed by the TRiPoD

ERC-Advanced EU (322856) grants to D.K. N.S. is supported by the

European Research Council (project ERC- STG MetaPG-716575).

L.D.S. is funded by a Roux-Cantarini fellowship from the Institut

Pasteur (Paris, France). Bristol-Myers-Squibb provided resources

to support translational research related to the NIVOREN clinical

trial enrolling kidney cancer patients.Competing interests:R.D.,

D.R., L.Z., and G.K. are cofounders of everImmune, a biotech

company devoted to the use of commensal microbes for the

treatment of cancers. R.D. is a full-time employee of everImmune.

L.Z., A.F., V.C., and R.D. are inventors on a patent application (WO/

2019/129753) submitted by Institute Gustave Roussy/INSERM/

University Paris Saclay that covers“Immunogenic sequences

from a Phage Tail Length Tape Measure Protein, bacteria

expressing the same and their use in treating a cancer.”

Data and materials availability:E. hirae13144 isolate and

E. hiraeisolates IGR4 and IGR11 are available from U1015 INSERM

under a material transfer agreement (with Gustave Roussy

Technology Transfer) or from the repository of Institut Pasteur

listed asEnterococcus hiraedeposited at the Collection Nationale

de Cultures de Microorganismes (CNCM) of Pasteur Institute,

Paris: strains 13144 (EHFS001), deposited on November 7, 2013,

under the number I-4815; IGR4 deposited on November 27, 2017,

under the number CNCM I-5260; and IGR11 deposited on

November 27, 2017, under the number CNCM I-5261. Bacteria

genomes sequenced in this study have been deposited in the

NCBI GenBank under the accession number PRNJA639126.

Microbiome-related mass spectrometry data have been deposited

(https://doi.org/10.35081/bd5t-nm23).

SUPPLEMENTARY MATERIALS

science.sciencemag.org/content/369/6506/936/suppl/DC1

Materials and Methods

Figs. S1 to S15

Tables S1 to S12

Statistical Report

References ( 38 – 52 )

View/request a protocol for this paper fromBio-protocol.

19 March 2019; resubmitted 28 February 2020

Accepted 23 June 2020

10.1126/science.aax0701

Fluckigeret al.,Science 369 , 936–942 (2020) 21 August 2020 7of7

RESEARCH | RESEARCH ARTICLE